Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2

Journal of Rheumatology

Volumn 39, Issue 5, 2012, Pages 979-985

  Antonelli, Alessandro ^a   Fallahi, Poupak ^a   Ferrari, Silvia Martina ^a   Giuggioli, Dilia ^b   Colaci, Michele ^b   Di Domenicantonio, Andrea ^a   Ferri, Clodoveo ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

CCL2; CXCL10; Cytokines; Fibroblasts; Interleukin 6; Scleroderma

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; FIBROBLAST; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TH1 CELL; TH2 CELL;

ADULT; AGED; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CXCL10; FEMALE; FIBROBLASTS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860734406     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111132     Document Type: Article

References (46)

1. Kraaij MD, van Laar JM. The role of B cells in systemic sclerosis. Biologics 2008;2:389-95.
2. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954-66. (Pubitemid 44411958)
3. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6. (Pubitemid 32781022)
4. Zurita-Salinas CS, Richaud-Patin Y, Krötzsch-Gómez E, Llorente L, Alcocer-Varela J, Díaz-de-León L, et al. Spontaneous cytokine gene expression by cultured skin fibroblasts of systemic sclerosis. Correlation with collagen synthesis. Rev Invest Clin 1998;50:97-104. (Pubitemid 128554655)
5. Feghali CA, Bost KL, Boulware DW, Levy LS. Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity 1994;17:309-18. (Pubitemid 24238337)
6. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19:1207-11.
7. Kawaguchi Y, McCarthy SA, Watkins SC, Wright TM. Autocrine activation by interleukin 1-alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 2004;31:1946-54. (Pubitemid 39336718)
8. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1-alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999;103:1253-60. (Pubitemid 29218295)
9. Fukasawa C, Kawaguchi Y, Harigai M, Sugiura T, Takagi K, Kawamoto M, et al. Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): Role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003;33:2792-800. (Pubitemid 37337145)
10. Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002;46:1602-13. (Pubitemid 34620208)
11. Takemura H, Suzuki H, Fujisawa H, Yuhara T, Akama T, Yamane K, et al. Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. J Rheumatol 1998;25:1534-9. (Pubitemid 28364759)
12. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998;25:296-301. (Pubitemid 28088258)
13. Hasegawa M, Sato S. The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis. Front Biosci 2008;13:3637-47. (Pubitemid 351594648)
14. Yamamoto T. Pathogenic role of CCL2/MCP-1 in scleroderma. Front Biosci 2008;13:2686-95. (Pubitemid 351599712)
15. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis - A longitudinal study. Rheumatology 2008;47:45-9. (Pubitemid 350286260)
16. Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, Ferrari SM, et al. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol 2008;35:1809-11.
17. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000;404:407-11. (Pubitemid 30164344)
18. Karrer S, Bosserhoff AK, Weiderer P, Distler O, Landthaler M, Szeimies RM, et al. The-2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol 2005;124:92-8. (Pubitemid 40100953)
19. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (CCL2, MIP-1 alpha, and MIP-1 beta) in patients with systemic sclerosis: CCL2 and MIP-1 alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159-65. (Pubitemid 29292792)
20. Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998;114:293-300. (Pubitemid 28505732)
21. Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL. Chemokine expression by systemic sclerosis fibroblasts: Abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001;44:1382-6. (Pubitemid 32537537)
22. Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001;31:2936-41. (Pubitemid 32994545)
23. Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001;26:133-9. (Pubitemid 32510721)
24. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665-78. (Pubitemid 33049344)
25. Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 2004;35:43-51. (Pubitemid 38759740)
26. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
27. Arnett FC. Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol 2006;18:579-81. (Pubitemid 44607409)
28. Varga J, Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67. (Pubitemid 46348510)
29. Giacomelli R, Cipriani P, Fulminis A, Barattelli G, Matucci-Cerinic M, D'Alò S, et al. Circulating gamma/delta t lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol 2001;125:310-5. (Pubitemid 32758443)
30. Valentini G, Baroni A, Esposito K, Naclerio C, Buommino E, Farzati A, et al. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 2001;21:210-7. (Pubitemid 32434308)
31. Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010;49:2408-12.
32. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: Cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002;168:3088-98. (Pubitemid 34211692)
33. Zhang K, Gharaee-Kermani M, Jones ML, Warren JS, Phan SH. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. J Immunol 1994;153:4733-41.
34. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003;121:510-6. (Pubitemid 37072262)
35. Inoshima I, Kuwano K, Hamada N, Hagimoto N, Yoshimi M, Maeyama T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2004;286:L1038-44. (Pubitemid 38508815)
36. Moore BB, Paine R 3rd, Christensen PJ, Moore TA, Sitterding S, Ngan R, et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 2001;167:4368-77. (Pubitemid 32954313)
37. Okuma T, Terasaki Y, Kaikita K, Kobayashi H, Kuziel WA, Kawasuji M, et al. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol 2004;204:594-604. (Pubitemid 39585959)
38. Yamana J, Santos L, Morand E. Enhanced induction of LPS-induced fibroblast CCL2 by interferon-gamma: Involvement of JNK and MAPK phosphatase-1. Cell Immunol 2009;255:26-32.
39. Struyf S, Van Collie E, Paemen L, Put W, Lenaerts JP, Proost P, et al. Synergistic induction of MCP-1 and -2 by IL-1 beta and interferons in fibroblasts and epithelial cells. J Leukoc Biol 1998;63:364-72. (Pubitemid 28106851)
40. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000;164:6503-8. (Pubitemid 30408835)
41. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: Modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006;91:614-20. (Pubitemid 43236933)
42. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, et al. Monokine induced by interferon gamma (IFN gamma) (CXCL9) and IFN gamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: Modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009;94:1803-9.
43. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007;127:281-92. (Pubitemid 46106903)
44. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, et al. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004;89:5496-9. (Pubitemid 39518431)
45. Antonelli A, Ferri C, Ferrari SM, Colaci M, Giuggioli D, Fallahi P. Induction of CXCL10 secretion by interferon-γ and tumour necrosis factor-α and its inhibition by peroxisome proliferator-activated receptor-γ agonists in cultured scleroderma fibroblasts. Br J Dermatol 2010;163:650-1.
46. Baraut J, Michel L, Verrecchia F, Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010;10:65-73.